审阅要点
药品记录或公司供应链披露针对其特定对象。请另行确认拟议货物的分类、文档及责任方。
准备咨询
请提供产品或序列、配置、数量、目的地和所需文档，以便团队评估范围并确认可提供的信息。
来源与核实范围
Pharmaceutical imports from China, HS 30, 2025
WITS / UN Comtrade
来源详情（原文语言）
- 范围
- Reported pharmaceutical imports from China, HS chapter 30
- 文件位置
- United States and European Union rows; trade value 1000 USD
- 局限
- Do not add EU aggregate to member countries. Not peptide-only trade.
- 陈述核实日期
- 2026-09-09
Eli Lilly and Company Form 10-K, fiscal year 2025
SEC · filing by Eli Lilly and Company
来源详情（原文语言）
- 范围
- Lilly reports reliance on China-based suppliers for portions of its supply chain
- 文件位置
- Manufacturing and supply, p. 21; third-party supply chain risk factors
- 局限
- Does not identify Bolang, peptide purchases from Bolang, partnership, endorsement or certification.
- 陈述核实日期
- 2026-09-09
Importing Biological Materials into the United States
U.S. Customs and Border Protection
来源详情（原文语言）
- 范围
- US import requirements depend on material and applicable agencies
- 文件位置
- Agency requirements and scope
- 局限
- Research use does not automatically remove applicable requirements; no universal catalog admission claim.
- 陈述核实日期
- 2026-09-09